Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
13 hedge funds and large institutions have $595K invested in Timber Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
13% less funds holding
Funds holding: 15 → 13 (-2)
43% less capital invested
Capital invested by funds: $1.04M → $595K (-$447K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$18K |
| 2 |
Barclays
London,
United Kingdom
|
+$14.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$10.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$249K |
| 2 |
BlackRock
New York
|
-$34.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 4 |
Two Sigma Investments
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $369K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $75K | +$9.81K | +673 | +16% |
|
|
3
Northern Trust
Chicago,
Illinois
| $38K | +$18K | +1,233 | +102% |
|
4
State Street
Boston,
Massachusetts
| $35K | – | – | – |
|
|
5
Barclays
London,
United Kingdom
| $33K | +$14.6K | +1,000 | +93% |
|
|
6
UBS Group
Zurich,
Switzerland
| $16K | +$12.1K | +829 | +525% |
|
|
TSS
7
Two Sigma Securities
New York
| $15K | +$10.4K | +715 | +310% |
|
8
Citigroup
New York
| $6K | +$5.68K | +390 | +3,900% |
|
|
9
Renaissance Technologies
New York
| $5K | -$249K | -17,109 | -98% |
|
|
VF
10
Virtu Financial
New York
| $3K | +$3.18K | +218 | New |
|
|
WWP
11
WR Wealth Planners
Columbia,
Missouri
| $1 | – | – | – |
|
|
12
BlackRock
New York
| – | -$34.7K | -2,378 | Closed |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$19K | -987 | Closed |
|
|
14
Two Sigma Investments
New York
| – | -$17K | -872 | Closed |
|
|
SPIA
15
Steward Partners Investment Advisory
New York
| – | +$15 | +1 | New |
|
16
Wells Fargo
San Francisco,
California
| – | +$15 | +1 | +14% |
|
TMBR Hedge Fund Activity: Q2 2022 in Review
13 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2022, worth a combined $595K — down 43% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TMBR and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was Northern Trust, adding an estimated $18K. The largest seller was Renaissance Technologies, cutting an estimated $249K.
- 13 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2022, down from 15 in Q1 2022.
- Funds reported $595K of Timber Pharmaceuticals, Inc. stock for Q2 2022, down 43% quarter-over-quarter.
- 2 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2022 was Northern Trust, an estimated $18K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2022 was Renaissance Technologies, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2022.